(Q37127088)

English

Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin.

scientific article published on 17 January 2013

Statements

Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin. (English)
Jason Gee
Howard Bailey
Kyungmann Kim
Jill Kolesar
Tom Havighurst
Kendra D Tutsch
William See
Michael B Cohen
Nick Street
Leon Levan
David Jarrard
17 January 2013
970-978

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit